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Objectives: This study compares the dosimetry and efficiency of two modern radiosur-
gery [stereotactic radiosurgery (SRS)] modalities for multiple brain metastases [Gamma 
Knife (GK) and LINAC-based RapidArc/volumetric modulated arc therapy], with a special 
focus on the comparison of low-dose spread.
Methods: Six patients with three or four small brain metastases were used in this study. 
The size of targets varied from 0.1 to 10.5 cc. SRS doses were prescribed according 
to the size of lesions. SRS plans were made using both Gamma Knife® Perfexion and 
a single-isocenter, multiple non-coplanar RapidArc®. Dosimetric parameters analyzed 
included RTOG conformity index (CI), gradient index (GI), 12 Gy isodose volume (V12Gy) 
for each target, and the dose “spread” (Dspread) for each plan. Dspread reflects SRS 
plan’s capability of confining radiation to within the local vicinity of the lesion and to not 
spread out to the surrounding normal brain tissues. Each plan has a dose (Dspread), 
such that once dose decreases below Dspread (on total tissue dose–volume histogram), 
isodose volume starts increasing dramatically. Dspread is defined as that dose when 
volume increase first exceeds 20 cc/0.1 Gy dose decrease.
results: RapidArc SRS has smaller CI (1.19  ±  0.14 vs. 1.50  ±  0.16, p  <  0.001) 
and larger GI (4.77 ± 1.49 vs. 3.65 ± 0.98, p < 0.01). V12Gy results were comparable 
(2.73 ± 1.38 vs. 3.06 ± 2.20 cc, p = 0.58). Moderate to lower dose spread, V6, V4.5, 
and V3, were also equivalent. GK plans achieved better very low-dose spread (≤3 Gy) 
and also had slightly smaller Dspread, 1.9 vs. 2.5 Gy. Total treatment time for GK is 
estimated between 60 and 100 min. GK treatments are between 3 and 5 times longer 
compared to RapidArc treatment techniques.
conclusion: Dosimetric parameters reflecting prescription dose conformality (CI), dose 
fall off (GI), radiation necrosis indicator (V12Gy), and dose spread (Dspread) were compared 
between GK SRS and RapidArc SRS for multi-mets. RapidArc plans have smaller CI but 
larger GI. V12Gy are comparable. GK appears better at reducing only very low-dose spread 
(<3 Gy). The treatment time of RapidArc SRS is significantly reduced compared to GK SRS.
Keywords: VMaT, rapidarc, gamma Knife, srs, brain metastasis
TaBle 1 | Prescription dose and tumor volumes of each target in this 
study.
Patient 
no.
no. of 
targets
Total tumor vol. 
(cc)
Tumor vol. 
(cc)
Prescription 
dose (gy)
1 3 5.32 2.53 16
0.81 24
1.98 20
2 3 2.08 0.41 24
0.51 24
1.16 18
3 3 1.19 0.41 24
0.52 24
0.26 24
4 3 5.13 4.62 18
0.12 24
0.39 24
5 3 11.14 10.51 15
0.35 24
0.28 24
6 4 1.70 0.68 24
0.56 24
0.46 24
0.4 24
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inTrODUcTiOn
Brain metastases represent the most frequent brain tumor and are 
a significant cause of morbidity and mortality. Surgery, whole-
brain radiation treatment (WBRT), and stereotactic radiosurgery 
(SRS) are all used in the treatment of brain metastases (1–9). 
Radiosurgery has emerged as a common treatment modality for 
brain metastases since the introduction of Gamma Knife (GK) 
(10), but now advances in technology permits newer techniques, 
such as Cyberknife® and linear accelerator (LINAC)-based volu-
metric modulated arc therapy (VMAT) treatment.
Linear accelerator-based systems are capable of achieving 
delivering treatment techniques common to GK SRS. These 
include (a) an ensemble of convergent beams or arcs used to tar-
get a circumscribed, well-defined lesion, (b) high doses delivered 
to the planning target volume (PTV), and (c) steep dose gradients 
created at the margin of the tumor and normal tissue, thus ensur-
ing a low dose outside the target. The common techniques of 
LINAC SRS include the use of multiple conformal arcs or multiple 
static intensity modulated beams (IMRT), which further evolved 
into VMAT (11), to treat a single target positioned at the LINAC 
isocenter. The treatment time for one target typically ranges from 
15 to 20 min, which becomes the limit factor to treat more than 
4–5 brain metastases in a single session.
Some studies proposed treating multiple brain metastases SRS 
with a single virtual isocenter using VMAT technique (12–19), and 
some compared to GK (16–19). While some previous studies have 
appeared to show GK as superior to LINAC SRS with regard to normal 
brain exposure (16–18), a more recent study suggested equivalent 
low-dose spread and increased delivery efficiency (19) when using 
non-coplanar RapidArc [one of the VMAT techniques implemented 
by Varian Eclpise treatment planning system (TPS)]. However, the 
low-dose spread in this study was defined as 25% of prescription dose 
(4.5 Gy as the lowest comparison dose), which may not be as low as 
the dose used by other controversy studies. Therefore, we performed 
the current study to evaluate the dosimetry and efficiency of these 
two modalities  –  GK and LINAC single-isocenter non-coplanar 
RapidArc SRS for multiple brain metastases, with a special focus on 
the comparison of very low-dose spread (≤3 Gy). The other differ-
ence in our study is that a newer model of GK (Perfexion™) is used 
as compared to the older model (C/4C) used in literature (19).
MaTerials anD MeThODs
Patients
We used the image data of six patients with three to four brain 
metastases who received SRS treatment at our institution. The 
study was approved by our Institutional Review Board (IRB). 
The cases were planned with GammaPlan®, the Gamma Knife 
Perfexion TPS (Elekta AB, Stockholm Sweden), and Eclipse™ 
TPS using RapidArc®, a particular implementation of VMAT 
(Varian Medical Systems, Palo Alto, CA, USA) on Varian delivery 
systems, the more recent versions of which, allow for the delivery 
of multiple non-coplanar arcs. Each of the GK plans was designed 
by an experienced GK physicist and approved by an attending 
neurosurgeon and radiation oncologist. All RapidArc plans were 
generated by an experienced physicist dedicated to SRS.
imaging Protocol
Our treatment planning employed both high-quality magnetic 
resonance imaging (MRI), from a 1.5-T or 3.0-T scanner, and 
high-resolution computed tomography (CT) images. The CT 
technique utilized a 512 × 512-pixel resolution and slice thick-
ness of 1.25  mm to reduce partial volume effects. Contrast 
enhanced, thin cut (1.0–1.5 mm thickness) 3D T1-weighted MRI 
was acquired to optimize planning fidelity. Target and normal 
structure contours were outlined based on the high-resolution 
MRI and approved by an attending neurosurgeon and radiation 
oncologist. The contoured MR images were then fused to the CT. 
The same sets of images and structures were used in both Elekta 
GammaPlan and Varian Eclipse TPSs.
radiation Dose
Stereotactic radiosurgery doses, prescribed according to size of 
the lesions, varied from 15 to 24 Gy according to RTOG 9508 
(20). Radiation doses were modified if unable to meet nearby 
organ at risk (OAR) tolerance, including optic nerve and chiasm 
max dose of 10 Gy and brainstem max dose of 12 Gy. Prescription 
dose and tumor volume of each target are listed in Table 1.
gamma Knife Treatment Planning
Gamma Knife plans were performed for all patients using the 
Elekta GammaPlan TPS (version 10.1) for a Gamma Knife 
Perfexion treatment unit. The Perfexion has 192 Co-60 sources, 
which are placed on eight sectors. Each position corresponds to 
a different size collimator. Each sector has 24 sources and three 
different sizes of open collimators are available for each source 
(16, 8, and 4 mm) as well as a blocked collimator. Because each of 
the eight sectors can move independently, it is possible to create 
plans with composite multiple shots where each sector is of dif-
ferent collimator size. Treatment plan of each lesion starts from 
automatic shots fill in with composite small to medium sized 
TaBle 2 | Planning parameters for gamma Knife Perfexion plans.
Patient 
no.
no. of 
targets
number of 
shots
Beam-on 
time (min)
est. total tx time 
(min)
1 3 43 83.5 100
2 3 15 72.2 87
3 3 4 47 56
4 3 19 70 84
5 3 26 93 112
6 4 10 64 77
TaBle 3 | Planning parameters for single-isocenter VMaT plan.
Patient 
no.
no. of 
targets
no. of 
arcs
Table angles (Varian  
iec scale)
arc length Monitor  
units (MU)
Beam-on  
time (min)
est. total tx  
time (min)
1 3 4 45, 0, 335, 300 170, 120, 140, 140 7000 5.0 15
2 3 6 70, 40, 10, 0, 335, 305 160, 150, 40, 130, 160, 150 8300 5.9 18
3 3 6 50, 25, 0, 340, 315, 290 160, 160, 130, 140, 140, 150 9600 6.9 21
4 3 5 80, 45, 20, 353, 300 140, 140, 150, 140, 150 10,130 7.2 22
5 3 5 60, 20, 345, 310, 270 120, 120, 120, 140, 140 8660 6.2 19
6 4 5 70, 40, 10, 0, 300 170, 170, 170, 140, 140 9750 7.0 21
February 2016 | Volume 6 | Article 263
Liu et al. SRS for Multiple Brain Metastases
Frontiers in Oncology | www.frontiersin.org
collimators depending on the volumes of the target, followed by 
an optimization with inverse planning setting of 99% coverage. 
After the initial optimization, it usually achieves ~95% coverage 
with dose distribution that is not very conformal. Planner adjust-
ments are then introduced to achieve >99.5% volume coverage 
by the prescription dose and a more conformal dose distribution. 
Adjustment includes changing position and weight of each exist-
ing shot and adding new shots. Multiple shots plans were usually 
used to increase conformity, rather than fewer shots to minimize 
treatment time. All targets are prescribed to 50% isodose line. The 
“TMR 10” dose algorithm is used in Gamma plan calculation. 
Detailed GK planning parameters are listed in Table 2.
rapidarc Treatment Planning
For all patients in the study, RapidArc plans were optimized using 
four to six non-coplanar partial arcs (21). Collimator and couch 
angles as well as single arc lengths were optimized for each indi-
vidual case with small adjustments to our established template. 
The detailed planning parameters for each case are listed in 
Table 3. Inverse planning was performed with the Varian Eclipse 
TPS (version 11) and dose calculation with a grid resolution of 
1.0 mm. Three layers of tuning rinds, as described by Clark et al. 
(14), were constructed to control the dose–volume constraints 
corresponding to the high-, mid-, and low-dose levels, where 
“high” is the prescription dose of each target, “medium” the 12-Gy 
dose level, and “low” the 6-Gy dose level. The outer diameters 
of each layer of rinds depend on the size of the target. All plans 
were constructed using the 6-MV flatten filter free (FFF) beam, 
generated by a TrueBeam STx radiosurgery system equipped with 
a high-definition (2.5 mm) multileaf collimator (MLC). The High 
Intensity Mode unflattened 6 MV beam delivers radiation at a dose 
rate of 1400 cGy/min. Prendergast first showed the efficiency ben-
efit of unflattened beams for cranial treatments (22). The HD120 
MLC™ has 120 leaves with a leaf width projected at isocenter 
of 2.5 mm for the central 8.0-cm region and 5.0 mm for the two 
7.0-cm peripheral regions (23, 24). One isocenter was used for all 
targets and was placed at the center of mass of all targets deter-
mined by the TPS. Each lesion must have >99.5% volume covered 
by prescription dose. “AAA” algorithm with heterogeneous cor-
rection, 1 mm calculation grid is used for final dose calculation.
evaluation Tools
Dosimetric parameters for analysis included RTOG conformity 
index (CI), gradient index (GI), 12  Gy isodose volume (V12Gy) 
for each target, and dose spread (Dspread) for each plan. RTOG 
CI = PV/TV, where PV is the prescription volume and TV is the 
target volume (25). Paddick GI =  PV50%/PV, where PV50% is 
50% of the prescription isodose volume and PV is the prescription 
volume (26). Dspread reflects the SRS plan’s capability of confining 
radiation to within the lesions’ local vicinity minimizing spread to 
surrounding normal brain tissues. Each plan has a dose (Dspread) 
on the total tissue DVH, such that once dose drops below Dspread, 
the isodose volume starts increasing dramatically. In this study, 
Dspread is defined at the dose at which the volume increase first 
exceeds 20 cc/0.1 Gy drop in dose. For the Eclipse TPS, it is the dose 
at 2 cc/cGy on a differential DVH curve for normal brain tissue. 
Treatment times for RapidArc SRS were estimated using the summa-
tion of patient setup time, image guidance and verification (IGRT) 
time, and radiation delivery time. Radiation delivery is based on the 
total dose divided by 1400 cGy/min dose rate. Treatment time for 
GK SRS was estimated using the summation of patient setup time, 
shot transition time, and net beam-on time. Beam-on time assumes 
new Co-60 sources whose dose rate is 360 cGy/min.
In order to compare the results across different TPSs, the 
three-dimensional (3D) radiation dose matrix of both GK and 
RapidArc SRS plans were exported in DICOM RT format to a 
third party system (MIMVISTA). Both dose matrices encompass 
the entire brain at a dose calculation resolution of 1.0 mm.
statistics
Prism® version 5.0 was used to process data and perform statistical 
analyses. Direct comparison was performed via paired Wilcoxon 
signed rank test; multivariate regression was performed via least 
squares regression with an identity link function. p-values <0.05 
were considered significant.
resUlTs
Clinical acceptable plans were achieved by both GK SRS and 
RapidArc SRS. Figure 1 shows the isodose distribution of both 
GK plan and RapidArc plan for patient #1, a typical patient. 
FigUre 1 | isodose distribution of a single-isocenter VMaT (rapidarc) srs plan (a) and gamma Knife (B) Perfexion plan for the same patient 
(patient #1). Isodose lines are 24, 20, 16, 12, 6, and 3 Gy. (a) Isodose distribution of a single-isocenter VMAT (RapidArc) SRS plan for patient #1. (B) Isodose 
distribution of Gamma Knife Perfexion SRS plan for patient #1.
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Figure 2 shows the dose–volume histogram of three lesions and 
normal brain tissues of both plans for this patient.
RapidArc SRS has smaller CI (1.19 ±  0.14 vs. 1.50 ±  0.16, 
p <  0.001), however, a larger GI (4.77 ±  1.49 vs. 3.65 ±  0.98, 
p < 0.01). The larger GI values for the RapidArc SRS plan are not 
because they have larger 50% prescription isodose volume but 
because they all have smaller 100% prescription isodose volume. 
Therefore, instead of comparing GI values, which are not a valid 
comparison, the absolute volume that receives more than 12 Gy 
(V12Gy) is compared in our study. V12Gy was chosen because it is a 
known predictor of radiation toxicity in normal brain tissues (27). 
The V12Gy of each individual targets were comparable between 
GK and RapidArc, 3.06 ±  2.20 vs. 2.73 ±  1.38 cc, respectively, 
p = 0.58. Table 4 shows the CI, GI, and V12Gy of each individual 
targets. To further evaluate the impact on the dose to normal 
brain tissue outside the target, we compared multiple dosimetric 
parameters for low-dose spread. Lower dose spread V6, V4.5, and 
V3 were also equivalent (Table 5).
FigUre 2 | Dose–volume histogram (DVh) comparison of a single-isocenter VMaT (rapidarc) srs plan and gamma Knife Perfexion plan for the 
same patient (patient #1) showing background dose to normal tissue and DVh for the 16, 20, and 24 gy treatment of the larger to the smaller target, 
respectively.
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To further evaluate the low-dose spread between the two tech-
niques, we also evaluated the dose to 100, 200, and 300 cc normal 
brain tissues (Table 5). The dose to 100 cc (D100cc) is equivalent. 
The dose to 200 cc (D200cc) is approaching a statistically significant 
difference and favors GK plans, 2.6 vs. 3.2 Gy, p = 0.06. The dose 
to 300 cc normal brain tissue (D300cc) is better for GK plans, 2 vs. 
2.6 Gy, p < 0.05. However, the very small absolute difference of 
0.6 Gy is not considered clinically significant in either case.
In addition, we also used the parameter of Dspread, which is 
defined at the dose when volume increase exceeds 20 cc/0.1 Gy 
dose decrease, for easy comparison of low-dose spread between 
plans. GK plan had smaller Dspread, 1.9 vs. 2.5  Gy, p =  0.01. 
Again, the small difference at this very low-dose level is not 
expected to be clinically significant.
We also evaluated the treatment delivery time for both GK and 
RapidArc SRS plans. For these six cases, beam-on time averages 
~72 min for GK SRS and 6.4 min for RapidArc SRS (Table 5). 
Total treatment time for GK is estimated between 56 and 112 min 
including setup and shot transition time, based on new radia-
tion sources. Total treatment time for RapidArc SRS is estimated 
between 15 and 22 min including setup, imaging guidance, and 
treatment table rotation time between arcs. It is average ~4.5 
times shorter compared to GK treatment (Tables 2 and 3).
DiscUssiOn
Since the invention of GK in the 1950s, multiple C-arm LINAC 
treatment machines have been commonly used for cranial 
radiosurgery. C-arm LINAC treatment machines have the advan-
tage of being versatile, capable of delivering treatment to extrac-
ranial sites as well as intracranial sites and capable of delivering 
multi-fraction treatment with easily reproducible non-invasive 
target immobilization and localization. With the availability of 
image-guided radiation therapy, advances in computer science, 
and improvement of treatment delivery hardware, such as high-
definition MLCs, which allow for the simultaneous delivery of 
shaped dose to multiple targets, modern LINACs are able to 
achieve the same degree of accuracy and precision of the GK but 
with more treatment efficiency. With the more recent develop-
ment of VMAT optimization planning capability, LINACs are 
able to simultaneously treat multiple targets with high plan qual-
ity and even greater efficiency. This becomes particular appealing 
with SRS for multiple brain metastases. In our current study, we 
have demonstrated, along with others (19), that RapidArc-based 
treatment planning can achieve the same target coverage as GK, 
with similar clinically acceptable dosimetry results (Table  4). 
Even with multiple-shot optimized plans, the CI of GK plans are 
still inferior to that of RapidArc plans. The major concern for 
the RapidArc plans is the very low-dose spread to the normal 
brain tissue outside the treatment fields. Several other studies 
have evaluated this and had slightly different conclusions. We 
paid special attention to the low-dose spread in the current 
study. With our analysis, the statistical difference in low-dose 
spread is only at a very low-dose level, particularly <3 Gy. This 
small amount of very low-dose spread is not considered clini-
cally significant and is comparable to the dose of one fraction of 
TaBle 5 | Dosimetric parameters of gamma Knife srs and rapidarc 
srs radiation treatment plans in this study.
gamma Knife rapidarc
Mean std. Mean std. p
V12 (patient composite) 10.85 7.2 9.7 5.1 0.63
V6 36.9 16.9 36.3 14.7 0.96
V4.5 86.7 29.8 99 27.3 0.15
V3 160.8 55.7 224 53 0.1
D100 4 0.9 4.6 0.6 0.3
D200 2.6 0.6 3.2 0.5 0.06
D300 2 0.4 2.6 0.4 <0.05
Dspread 1.9 0.73 2.5 0.2 0.01
Beam-on time 71.6 15.9 6.4 0.8 <0.01
Est. total tx time 85.9 19.1 19.3 2.6 <0.01
TaBle 4 | comparison of conformity index and normal tissue V12gy of each target in this study.
normal tissue
Patient # Target # Target vol. (cc) conformity index gradient index V12gy (cc)
gKP rPa gKP Pra gKP rPa
1 1 2.53 1.62 1.15 3.42 4.28 4.80 3.45
2 0.81 1.63 1.17 3.75 4.63 4.14 3.59
3 1.98 1.60 1.14 3.21 3.92 5.76 4.51
2 4 0.41 1.27 1.12 3.46 5.04 1.39 1.91
5 0.51 1.43 1.14 2.82 4.55 1.55 2.13
6 1.16 1.78 1.38 2.75 4.54 2.72 3.21
3 7 0.41 1.54 1.15 2.56 4.68 1.20 1.91
8 0.52 1.35 1.10 3.71 4.25 2.08 2.19
9 0.26 1.58 1.23 3.88 5.34 1.33 1.54
4 10 4.62 1.29 1.15 3.64 3.69 7.23 6.48
11 0.12 1.83 1.67 3.32 10.30 0.61 1.94
12 0.39 1.51 1.26 2.76 5.14 1.24 2.13
5 13 10.51 1.36 1.07 2.69 2.58 8.64 5.34
14 0.35 1.49 1.26 4.60 5.20 2.04 1.94
15 0.28 1.68 1.21 6.40 5.38 2.73 1.55
6 16 0.68 1.41 1.09 4.38 4.07 3.52 2.33
17 0.56 1.46 1.11 4.95 4.55 3.50 2.26
18 0.46 1.41 1.17 4.45 4.19 2.43 1.80
19 0.4 1.37 1.00 2.67 4.30 1.28 1.58
Mean 1.50 1.19 3.65 4.77 3.06 2.73
SD 0.16 0.14 0.98 1.49 2.20 1.38
p <0.001 p 0.01 p 0.58
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whole-brain irradiation. Extensive evidence have demonstrated 
that this is below the normal tissue tolerances of all sensitive brain 
structures, such as cochlea, optic nerve, chiasm, brainstem, and 
hippocampus (28–32). A recent assessment of the true risk of 
very low doses to normal brain tissues is highlighted in a recent 
study from the University of Florida (33). They analyzed 23 years 
of LINAC-based SRS data to address the long-term malignancy 
risk of low doses to normal brain compared to epidemiological 
brain tumor data in Florida. An analysis of the 627 cranial SRS 
patients (out of a total cohort of 2369 analyzed), who had five or 
more years of follow-up, showed that there was no increased risk 
of malignancy compared to the general population.
One of the most significant advantages of RapidArc compared 
to GK is the efficiency of treatment delivery. In our current study, 
we included patients with up to four brain metastases, based 
on level-1 evidence (5–7). For RapidArc SRS, beam-on time is 
<10 min for all the patients. Including setup and image-guidance 
procedures, the total treatment time can easily be <15–20 min. 
This efficiency benefit is primarily due to three key features of 
modern LINAC technology in this study: (1) single-isocenter–
non-coplanar VMAT (RapidArc SRS) treatment for all the targets 
(14, 19) vs. multiple isocenters corresponding to each individual 
target; (2) high-resolution MLC (HD120 MLC)  –  providing 
simultaneous high-resolution beam shaping (23, 24) of all the 
targets simultaneously from any angle vs. one target at a time; and 
(3) high dose rate (22) provided by the High Intensity Mode vs. 
the maximum dose rate of Co-60, which declines by 50% of max 
over 5 years. This not only increases the machine utilization but 
also improves the patient experience, particularly with a frame-
less immobilization system. The delivery efficiency of GK can be 
improved by using a large helmet size and less complex plans with 
fewer shots. However, this will result in a lower conformity index 
and increases low-dose spread. Recent high-level evidence from 
Japan suggests that SRS alone is safe and appropriate to consider 
for patients with up to 10 brain metastases (34). The advantage of 
delivery efficiency of RapidArc would be even greater.
Compared to other studies using single-isocenter coplanar 
VMAT (15, 16, 18) techniques, this study used a single-isocenter, 
multiple arc technique, with multiple treatment angles. And 
compared to previous published studies using RapidArc SRS 
single-isocenter multi arc VMAT techniques (13, 14, 19), the arc 
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geometry utilized in the current study is different. Multiple (4–6) 
non-coplanar partial arcs, between 110° and 150° arc lengths, 
were used, which avoids a transverse plane full 360° arc. The 
rationale is that for the transverse plane full 360° arc, since the 
second half arc enters through the exit of the first half arc, the 
normal brain tissue will receive more doses. By offsetting the 
arcs from the transverse plane, parallel-opposed beams will be 
avoided and the normal tissue isodose volume can be reduced, as 
Schell et al.’s study showed previously (21).
The target volumes in this study ranged from 0.1 to 10.5 cc, 
with most of them <2 cc (small targets). A recent planning com-
parison study for large target fractionated SRT using VMAT and 
GK for brain metastases and gliomas showed that GK produce 
better dose distribution for target volumes below 15  cc, while 
VMAT results in better dose conformity to the target and lower 
doses to the OARs for larger or irregular volumes (35).
It is worthwhile to point out that while the prescription dose 
covering the target volume is the same between GammaKnife 
and RaridArc SRS plans, the dose heterogeneity within the plan-
ning target volume (PTV) is much different. GK plan for each 
target in this study is prescribed to the standard 50% isodose 
line, which implies that the maximum dose within the PTV 
is twice as high as the prescription dose. RapidArc plan is an 
inverse planning process; the optimization goal to each PTV 
set by the planner is to have at least 99.5% volume receiving 
prescription dose. No constraint is set on the maximum dose. 
Therefore, there is no manual selection of a specific normaliza-
tion isodose line for RapidArc plans. The ratio of prescription 
dose to maximum dose for the 19 targets in RapidArc plans is 
63 ± 5% (range 54–74%).
cOnclUsiOn
Dosimetric parameters reflecting prescription dose conformal-
ity (CI), dose fall off (GI), radiation necrosis indicator (V12Gy), 
and dose spread (Dspread) were compared between GK and 
RapidArc for multi-mets SRS for a cohort of six patients with 
up to four metastases. RapidArc SRS plans have smaller CI but 
larger GI. V12Gy are comparable. GK SRS performs better at reduc-
ing very low-dose spread. However, the lowest doses to normal 
tissues in properly optimized RapidArc plans are not considered 
clinically significant (<3 Gy). While several prior studies demon-
strated the clinical feasibility of delivering high quality plans for 
single-isocenter RapidArc SRS for multiple cranial metastases, 
they did not address the question of very low dose to normal 
brain. This study quantified the low-dose spread in the case of 
three or four metastases. It also demonstrated that low dose is 
not clinically significant, even though it is larger than that of 
GK. On the other hand, the treatment time of RapidArc SRS 
is significantly reduced compared to GK SRS. Treatment time 
for SRS to multiple cranial metastases will become increasingly 
more relevant with the trend toward treating greater numbers of 
brain metastases in a single SRS session and as systemic therapies 
targeting the primary cancer succeed in extending survival in this 
increasing population of patients.
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